Stryker stock: Piper Sandler lifts target to USD 350

Piper Sandler raised its price target for Stryker on Monday, November 9, to 350 US dollars from 325 US dollars and kept an Overweight rating on the medical-device maker. Markets Insider, citing TipRanks and TheFly, said analyst Matt O'Brien based the update partly on a survey of 26 hip and knee surgeons.

Analyst view and operating signals

The survey pointed to weaker orthopedic conditions in recent months. Some physicians reported more patient affordability challenges, which Piper Sandler identified as a likely driver of the slowdown. The firm nevertheless expects procedure volumes to grow at a mid-single-digit rate through the end of 2026 and in 2027, suggesting that it sees the pressure as temporary rather than structural.

The analyst revision follows Stryker's softer third-quarter orthopedic performance and the company's reduced 2026 outlook. That combination leaves the shares exposed to further changes in hip and knee demand, while Piper Sandler's volume view offers a more constructive medium-term counterpoint. The higher target does not remove the execution and affordability risks highlighted in the survey.

Markets Insider reported the target change and rating on November 9. For investors, the next test is whether procedure volumes and Stryker's orthopedic execution improve enough to support the revised analyst view.

Stryker stock traded at 284.05 euros on Lang & Schwarz at 14:07 CET on Friday, November 13, 2026, 0.39 percent above the Xetra close of Thursday, November 12, at 282.95 euros.

Broader market context is available in the S&P 500 market reports.

More news and analysis are available on the Stryker stock page.